10493279 Canada Inc.
$75,000.00 CAD
≈ 12 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2022-2023
- Agreement period
- July 20, 2022 – May 1, 2023
- Reference
- nrc-cnrc:172-2022-2023-Q2-993313
Published purpose
Combination therapies have been evaluated in the clinic to achieve multi-functionality. However, some drug combination therapies can have multiple outcomes that may not be synergistic, causing side effects. In this project, the aim is to investigate the immunostimulatory properties of the drug product in cancer patient's immune cells, identify biomarkers in immune cells from cancer patients at different disease stages, and assess the anti-cancer efficacy of the product in a cancer disease model as a standalone treatment and in combination with other known therapy.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions